Sepio Capital LP Raises Stake in Teleflex Incorporated $TFX

Sepio Capital LP boosted its position in Teleflex Incorporated (NYSE:TFX - Free Report) by 83.1% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,687 shares of the medical technology company's stock after purchasing an additional 3,034 shares during the quarter. Sepio Capital LP's holdings in Teleflex were worth $924,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Banque Cantonale Vaudoise purchased a new stake in Teleflex in the 1st quarter worth approximately $27,000. MassMutual Private Wealth & Trust FSB lifted its stake in Teleflex by 103.1% in the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 197 shares of the medical technology company's stock worth $27,000 after purchasing an additional 100 shares in the last quarter. Costello Asset Management INC purchased a new stake in Teleflex in the 1st quarter worth approximately $28,000. Brooklyn Investment Group lifted its stake in Teleflex by 258.6% in the 1st quarter. Brooklyn Investment Group now owns 208 shares of the medical technology company's stock worth $29,000 after purchasing an additional 150 shares in the last quarter. Finally, Whipplewood Advisors LLC lifted its stake in Teleflex by 7,700.0% in the 1st quarter. Whipplewood Advisors LLC now owns 234 shares of the medical technology company's stock worth $32,000 after purchasing an additional 231 shares in the last quarter. 95.62% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Teleflex

In related news, CEO Liam Kelly bought 1,500 shares of the company's stock in a transaction dated Tuesday, August 5th. The stock was purchased at an average cost of $115.07 per share, with a total value of $172,605.00. Following the transaction, the chief executive officer owned 45,267 shares in the company, valued at approximately $5,208,873.69. This trade represents a 3.43% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jaewon Ryu bought 1,500 shares of the company's stock in a transaction dated Tuesday, August 5th. The stock was bought at an average cost of $115.00 per share, with a total value of $172,500.00. Following the completion of the transaction, the director owned 3,727 shares in the company, valued at approximately $428,605. This trade represents a 67.36% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders bought 5,500 shares of company stock worth $633,590. 1.40% of the stock is owned by corporate insiders.

Teleflex Trading Down 1.5%

Shares of TFX stock traded down $2.03 on Friday, hitting $130.47. 712,975 shares of the company's stock traded hands, compared to its average volume of 559,336. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.44 and a current ratio of 2.41. Teleflex Incorporated has a one year low of $108.90 and a one year high of $249.90. The company's fifty day simple moving average is $120.97 and its 200 day simple moving average is $126.08. The stock has a market capitalization of $5.77 billion, a price-to-earnings ratio of 30.70, a P/E/G ratio of 1.85 and a beta of 1.08.

Teleflex (NYSE:TFX - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.73 earnings per share for the quarter, beating the consensus estimate of $3.36 by $0.37. The business had revenue of $780.90 million during the quarter, compared to analysts' expectations of $771.53 million. Teleflex had a net margin of 6.31% and a return on equity of 15.08%. The firm's revenue for the quarter was up 4.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.42 EPS. Teleflex has set its FY 2025 guidance at 13.900-14.300 EPS. Equities analysts forecast that Teleflex Incorporated will post 13.98 EPS for the current year.

Teleflex Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, September 15th. Shareholders of record on Friday, August 15th will be given a dividend of $0.34 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $1.36 annualized dividend and a yield of 1.0%. Teleflex's dividend payout ratio is presently 32.00%.

Analyst Ratings Changes

TFX has been the topic of several recent analyst reports. Mizuho increased their target price on shares of Teleflex from $130.00 to $135.00 and gave the stock a "neutral" rating in a research note on Friday, August 1st. Wall Street Zen raised shares of Teleflex from a "buy" rating to a "strong-buy" rating in a report on Sunday, September 7th. Royal Bank Of Canada increased their price target on shares of Teleflex from $130.00 to $135.00 and gave the stock a "sector perform" rating in a report on Friday, August 1st. Finally, Wells Fargo & Company decreased their price target on shares of Teleflex from $137.00 to $131.00 and set an "equal weight" rating on the stock in a report on Friday, August 1st. One research analyst has rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $141.57.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.